Merit Award

Based on funding availability, a limited number of Merit Awards will be awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO Meeting and recognized for its scientific merit.

Merit Award recipients are honored with the opportunity to present their abstract at the Meeting, receive $1,000 in monetary support, complimentary registration for the Meeting, and access to reserved Meeting hotel reservation blocks. Merit Award candidates must apply for this award at the time of abstract submission.

Eligibility Criteria:
Applicants must meet the following criteria to be considered for a Merit Award:

  • Be the First Author on the abstract submission and agree to present the abstract if selected for presentation at the Meeting
  • Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD)
  • Be enrolled in an oncology fellowship training program, a radiation oncology residency program, or an equivalent oncology training program at the time of abstract submission
  • Work in an oncology laboratory or clinical research setting
  • Provide a letter of support from their training program director, indicating eligibility for the award
  • Provide a curriculum vitae

Special Merit Awards

Special Merit Awards are presented to trainees and junior faculty who have the top-ranking abstracts for the ASCO Annual Meeting. In addition to the stipend, recipients receive a plaque and are recognized at the ASCO Annual Meeting.

Bradley Stuart Beller Special Merit Award ($2,000)

This award is given to the fellow who has the highest ranking abstract overall in the Merit Award category as determined by the Scientific Program Committee. The award is funded through the Bradley Stuart Beller Endowment Fund.

Brigid Leventhal Special Merit Award 

This award is given to the fellow who submitted the top abstract in Pediatric Oncology as determined by the Scientific Program Committee.

Pain Special Merit Award

This award is given to the fellow who submitted the top abstract in Pain and Symptom Management Research as determined by the Scientific Program Committee.

James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology ($3,000)

This award was established in memory of James B. Nachman, MD, Professor of Pediatrics at the University of Chicago and an internationally renowned pediatric cancer expert. It is endowed through the James B. Nachman Pediatric Oncology Fund and will be given each year to a junior faculty member who submits the highest ranking abstract in pediatric oncology for the ASCO Annual Meeting as determined by the ASCO Scientific Program Committee. The recipient will receive $3,000 in monetary support to attend the Annual Meeting, complimentary registration for the Annual meeting and access to reserved Meeting housing. Candidates must apply for this award at the time of abstract submission.

The First Author must meet all of the following requirements to be considered for the James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology:

  • Hold a medical or doctoral degree (MD, PhD, DO, or DNP)
  • Be within 7 years of their first faculty appointment at the time of abstract submission
  • Conduct laboratory, population-based, or clinical research focused on childhood cancer
  • Agree to present the abstract at the ASCO Annual Meeting
  • In addition, the abstract must be selected for presentation in an Oral Abstract Session

Application Instructions

Consideration for a Merit Award is available on the abstract submitter for the ASCO Annual Meeting and other ASCO thematic meetings.

Abstract Submission Deadlines:

  • 2018 Gastrointestinal Cancers Symposium: September 26, 2017 at 11:59 PM EST (CLOSED)
  • 2018 ASCO-SITC Clinical Immuno-Oncology Symposium: October 3rd, 2017 at 11:59 PM EST (CLOSED)
  • 2018 Genitourinary Cancers Symposium: October 17th, 2017 at 11:59 PM EST (CLOSED)
  • 2018 Cancer Survivorship Symposium: October 24, 2017 at 11:59 PM EST (CLOSED)
  • 2018 ASCO Annual Meeting: February 13, 2018 at 11:59 PM EST

View All Recipients

2017 Annual Meeting Merit Award Recipients

Nabil Adra, MD
Indiana University
Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).
Saud AlDubayan, MD
Dana-Farber Cancer Institute
Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer.
Rita Assi, MD
The University of Texas M.D. Anderson Cancer Center
Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).
Min Sun Bae, MD, PhD
Memorial Sloan Kettering Cancer Center
Survival outcomes of screening with breast MRI in high-risk women.
Luis Baez-Vallecillo, MD
The University of Texas M.D. Anderson Cancer Center
Whole exome sequencing of metaplastic breast cancer (MpBC): Mutation status impacts survival.
Martin D. Berger, MD
University of Southern California
Genetic variations within the vitamin C transporter genes predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
Maria Carlo, MD
Memorial Sloan Kettering Cancer Center
Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B).
Jung-Woo Chae, PhD
National University of Singapore, Singapore
Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study.
Rajshekhar Chakraborty, MD
Mayo Clinic
Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.
Kamal Chamoun, MD
The University of Texas M.D. Anderson Cancer Center
Immune-related gene expression deficit of leukemia stem cells (LSC) in AML.
Aadel Chaudhuri, MD, PhD
Stanford University
Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.
Runzhe Chen, MD, MS
Southeast University, China
Synergism of gambogenic acid with bortezomib induce apoptosis of multiple myeloma.
Maxime Chenard-Poirier, MD
The Royal Marsden Hospital, United Kingdom
Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.
Michael Cheng, MD
Memorial Sloan Kettering Cancer Center
Potentially actionable somatic and germline alterations in advanced prostate cancer identified by next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA).
Yin Ting Cheung, PhD
St. Jude Children's Research Hospital
Biomarkers of brain injury and neurologic outcomes in children treated with chemotherapy for acute lymphoblastic leukemia (ALL).
Vincenza Conteduca, MD, PhD
The Institute of Cancer Research, United Kingdom
Androgen receptor (AR) status in plasma DNA associates with worse outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).
Gwen Dackus, MD
The Netherlands Cancer Institute
Long-term outcome of breast cancer patients diagnosed ≤40 years according to breast cancer subtype in the absence of adjuvant systemic therapy: The PARADIGM initiative.
Ibiayi Dagogo-Jack, MD
Massachusetts General Hospital
Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC).
Christine Dahl, MD, PhD
The Hospital for Sick Children, Canada
Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.
Katja De Paepe, MD
University Hospitals Leuven, Belgium
Whole body diffusion-weighted MRI can predict treatment outcome after one cycle of immunochemotherapy in aggressive non-Hodgkin lymphoma.
Joseph Del Paggio, MD
University of Toronto, Canada
Delivery of meaningful cancer care: Evaluating benefit and cost of cancer therapies using ASCO and ESMO frameworks.
Lisa Derosa, MD, PhD
Institut Gustave Roussy, France
Antibiotics prescription decreases progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.
Nicholas DeVito, MD
Duke University
Paracrine wnt-β-catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.
Clarissa Diniz
Johns Hopkins University
Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease.
Joshua Drago, MD
Massachusetts General Hospital
FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.
Temidayo Fadelu, MD
Dana-Farber Cancer Institute
Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance).
Farhad Fakhrejahani, MD
National Cancer Institute, National Institutes of Health
Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
Zachary Frosch, MD
Brigham and Women's Hospital
What does the general population think about chemotherapy shortages?
Ketan Ghate, MD
Queen's University, Canada
Resource utilization in patients with head and neck cancer: Analysis of CCTG HN6 (NCT00820248).
James Godfrey, MD
The University of Chicago
Autologous (auto) versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic (allo) hematopoietic cell transplantation (HCT) in follicular lymphoma (FL) patients (pts) with early chemoimmunotherapy failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
Chelain Goodman, MD
Northwestern University
Circulating tumor cell status and benefit of radiotherapy in stage I breast cancer.
Donna Graham, BSc, MB, MRCPUK
Queen's University, Ireland
Assessment of conditional survival probability in resected esophageal adenocarcinoma.
Gillian Gresham, MSc
Cedars-Sinai Medical Center
Assessing performance status and clinical outcomes with wearable activity monitors.
Nicolas Guibert, MD
Dana-Farber Cancer Institute
Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.
Evan Hall, MD, M.Phil.
Stanford University
Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?
Arielle Heeke, MD
Georgetown University
Prevalence of homologous recombination deficiency among all tumor types.
Robert Hillman, MD, PhD
The University of Texas M.D. Anderson Cancer Center
A novel genomic rearrangement signature predicts poor survival among women with high grade serous ovarian cancer.
Anna Hoppmann, MD, MPH
University of Alabama, Birmingham
Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.
Jessica Hudson, MD, MSC
Washington University
The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.
Ecaterina Ileana Dumbrava, MD
The University of Texas M.D. Anderson Cancer Center
Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.
Maya Ilowite, MD
Dana-Farber Cancer Institute
Disparities in prognosis communication among parents of children with cancer: The impact of race and ethnicity.
Anuradha Jayaram, MBBS, MRCP
The Royal Marsden Hospital, United Kingdom
Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.
Sheheryar Kabraji, MD
Massachusetts General Hospital
AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer patients.
Kai Kang, PhD
The Cleveland Clinic
Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC enhances immunotherapeutic effect of anti-PD1 in vivo.
Ciara Kelly, MBBS
Memorial Sloan Kettering Cancer Center
The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).
Daniel Khalaf, MD
British Columbia Cancer Agency
Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
Rebecca Kim, BA
The University of Pennsylvania
Chimeric antigen receptor (CAR) T cells induce clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer.
Vadim Koshkin, MD
The Cleveland Clinic
Molecular Profiling of Small Cell Bladder Cancer (SCBC) Reveals Gene Expression Determinants of an Aggressive Phenotype.
Curtis Lachowiez, MD
Oregon Health & Science University
Implementation of a screening program for identification of unrecognized inherited marrow failure syndromes.
Arjun Lakshman, MD, MRCP
Mayo Clinic
Natural history of t(11;14) multiple myeloma (MM).
Matteo Lambertini, MD
Institut Jules Bordet, Belgium
Safety of pregnancy in patients (pts) with history of estrogen receptor positive (ER+) breast cancer (BC): Long-term follow-up analysis from a multicenter study.
Kelsey Lau-Min, MD
Massachusetts General Hospital
Code status transitions from full code to do-not-resuscitate (DNR) among hospitalized patients with advanced cancer.
Rebecca Lee, MRCP, MBChB, BSc
Christie Hospital NHS Trust, United Kingdom
Use of circulating tumor DNA to predict survival in patients with resected high-risk stage II/III melanoma.
Roberto Leon-Ferre, MD
Mayo Clinic
Prognostic value of histopathology, stromal tumor infiltrating lymphocytes (sTILs) and adjuvant chemotherapy (AdjCT) in early stage triple negative breast cancer (TNBC).
Giulia Leonardi, MD
Dana-Farber Cancer Institute
Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders.
Oren Levine, MD, FRCPC
McMaster University
The PULSES project:  Teaching the vital elements of code status discussions to oncology residents.
Joline Lim, MBBS, MRCP
The Royal Marsden Hospital, United Kingdom
A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.
Richard Lin, MD, PhD
New York University
Polypharmacy and potentially inappropriate medication use in older patients with aggressive non-Hodgkin’s lymphoma (NHL) leads to inferior survival and increased treatment-related toxicities.
David Liu, MD, MS, MPH
Dana-Farber Cancer Institute
Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer.
Yichu Liu, PhD
The University of Texas at San Antonio
Assessment of tumor hypoxia in BEV resistant GBM using FMISO 18F-PET and MRI.
Kah Poh Loh, MBBCh
University of Rochester
Effect of exercise on quality of life (QoL) in 198 older patients with cancer: A URCC NCORP nationwide RCT.
Arin Madenci, MD, MPH
Boston Children's Hospital
Long-term incidence of venous thromboembolism (VTE) among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
Alexander Melamed, MD, MPH
Massachusetts General Hospital
Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all-cause mortality.
James Melotek, MD
University of Chicago
Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers.
Diana Miao, BA
Dana-Farber Cancer Institute
Loss-of-function of PBRM1 predicts response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.
Stephen Mihalcik, MD, PhD
Massachusetts General Hospital
A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).
Aaron Mitchell, MD
The University of North Carolina, Chapel Hill
Pharmaceutical industry payments and oncologist drug selection.
Yuji Miyamoto, MD, PhD, FACS
University of Southern California
Genetic variations in genes implicated in the axis are associated with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.
Chebli Mrad, MD
Icahn School of Medicine at Mount Sinai
Trends in aggressive care at the end-of-life for stage IV lung cancer patients.
Sweet Ng, MBBS
The University of Texas M.D. Anderson Cancer Center
Cost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy.
Terence NG, Bpharm
National University of Singapore
A genome-wide association study (GWAS) meta-analysis of chemotherapy-associated cognitive impairment (CACI) in Asian early-stage breast cancer patients (ESBC).
Tomohiro Nishijima, MD
University of North Carolina
Chemotherapy toxicity risk score (CTRS) for treatment decision in older patients with advanced solid cancer.
Sope Olugbile, MBBS
The University of Chicago
Sustained oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy.
Cecilia Ong, MD
Duke University
A population-based analysis of treatment and outcomes in 2,500 metaplastic breast cancer patients.
Emanuela Palmerini, MD
Istituto Ortopedico Rizzoli, Italy
Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1.
Ravi Parikh, MD
Brigham and Women's Hospital
A machine learning approach to predicting short-term mortality risk for patients starting chemotherapy.
Eileen Parkes, MBBCh, BAO
Queen's University, Ireland
PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.
Kelly Paulson, MD, PhD
Fred Hutchinson Cancer Research Center
Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.
Anita Peoples, PhD, MPH
University of Rochester
Effect of exercise on muscle immune response and mitochondrial damage and their relationship with cancer-related fatigue: A URCC NCORP study.
Mary Linton Peters, MD
Beth Israel Deaconess Medical Center
Germline genetic testing in unselected pancreatic ductal adenocarcinoma (PDAC) patients.
David Pinato, MD, PhD, MRCP
Imperial College London, United Kingdom
Programmed cell death ligands expression in pheochromocytomas (PCC) and paragangliomas (PGL): Relationship with the hypoxic response and malignant behaviour.
Philip Poorvu, MD
Dana-Farber Cancer Institute
Pregnancy after breast cancer: Results from a prospective cohort study.
Loredana Puca, PhD
Weill Cornell Medical College
Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC).
Stephen Ramey, MD
University of Miami
Factors impacting contemporary management of high-grade extremity sarcoma: An analysis of 12,020 patients.
Sangeetha Reddy, MD
The University of Texas M.D. Anderson Cancer Center
Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer.
Alexandre Reuben, PhD
The University of Texas M.D. Anderson Cancer Center
TCR repertoire sequencing of 254 resected non-small cell lung cancers reveals higher TCR clonality in normal tissues than tumor tissues.
Lisa Richters, MD
University Hospital Cologne
BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial.
Gareth Rivalland
Olivia Newton-John Cancer Research Institute
Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.
Simon Rodney, MBBS, MA, MSc
University College London, United Kingdom
Multi-region sequencing of penile cancer reveals distinct patterns of heterogeneous actionable mutations.
Daniele Rossini, MD
University of Pisa, Italy
Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.
Trevor Royce, MD MS
Brigham and Women's Hospital and Dana-Farber Cancer Institute
Cost effectiveness of surveillance for distant recurrence in extremity soft tissue sarcoma.
Joshua Sabari, MD
Memorial Sloan Kettering Cancer Center
PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC).
Daniel Shepshelovich, MD
Princess Margaret Cancer Centre, University of Toronto, Canada
Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.
Nicholas Short, MD
The University of Texas M.D. Anderson Cancer Center
Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.
Surbhi Sidana, MD
Mayo Clinic
Factors predicting organ response in light chain amyloidosis (AL).
Hao-Wen Sim, MBBS, FRACP
Princess Margaret Cancer Centre, University of Toronto, Canada
Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas.
Katharina Smetanay, MD
University Hospital Heidelberg, Germany
COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.
Aixa Soyano, MD
Mayo Clinic
Effects of age, immune landscape, and response to trastuzumab (H) in HER-2 positive (HER2+) breast cancer in NCCTG (Alliance)-N9831.
Mitsukuni Suenaga, MD, PhD
University of Southern California
Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.
Rudy Suidan, MD, MS
The University of Texas M.D. Anderson Cancer Center
Total and out-of-pocket costs of different primary management strategies in ovarian cancer.
Raghav Sundar, MBBS, MMed, MRCP, FAMS
The Royal Marsden Hospital, United Kingdom
TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.
Audree Tadros, MD, MPH
The University of Texas M.D. Anderson Cancer Center
Margins < 2 mm for Patients with Ductal Carcinoma in Situ is Not a Contraindication for Breast Conservation with Radiotherapy.
MinYuen Teo, MB, MRCP
Memorial Sloan-Kettering Cancer Center
DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).
Benjamin Teply, MD
Johns Hopkins University
Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).
Bibhusal Thapa, MBBS, MS
Olivia Newton-John Cancer Research Institute
Immune microenvironment in mesothelioma: Looking beyond PD-L1.
Davis Torrejon, MD
The University of California, Los Angeles
Interrogating resistance mechanisms to PD-1 blockade therapy with CRISPR.
Sara Valpione, MD
Christie Hospital NHS Trust, United Kingdom
Re-challenge with BRAF directed treatment: A multi-institutional retrospective study.
Qian Wang, MD, MPH
Icahn School of Medicine at Mount Sinai
Socio-demographic variations in lung cancer screening before and after USPSTF recommendation: Results from national health interview surveys (NHIS).
Rahma Warsame, MD
Mayo Clinic
How costs get discussed (or not) in routine oncology practice.
Anna Weiss, MD
The University of Texas M.D. Anderson Cancer Center
Effect of neoadjuvant chemotherapy regimen choice in patients with breast cancer with pathologic complete response.
Erica Weston, MD
Women and Infants Hospital in Rhode Island
The association between mindfulness and post-operative pain in gynecologic oncology patients undergoing minimally invasive hysterectomy.
Hans-Georg Wirsching, MD
University Hospital, Switzerland
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.
David Wise, MD PhD
Memorial Sloan Kettering Cancer Center
The immunomodulatory protein Dickkopf-1 (DKK1) defines a non-neuroendocrine subtype of metastatic castration-resistant prostate cancer (mCRPC) with low AR and low PSA expression.
Melisa Wong, MD
The University of California, San Francisco
Comparison of comorbidity measures to predict postoperative lung cancer survival in the National Cancer Database (AFT-03).
Risa Wong, MD
Massachusetts General Hospital
The importance of recognizing and addressing depression in patients with advanced cancer.
Shengyang Wu, MD
New York University
A DNA methylation-based classifier for accurate molecular diagnosis of bone sarcomas.
Irene Yu
British Columbia Cancer Agency, Canada
Comparison of 5-FU vs capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.
Jiaojiao Zhou, MD, PhD
The Second Affiliated Hospital of Zhejiang University
Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.

Supporters

The 2018 Merit Award is supported by:

                            


Friends and Family of Dr. and Mrs. Ronald Beller
Dr. and Mrs. Douglas W. Blayney
Ipsen Biopharmaceuticals, Inc.
Michael Kelley, MD & Elise Hoffman, PharmD
Kidney Cancer Association
Dr. Kathleen Pritchard Medicine Professional Corporation
Friends and Family of Dr. James B. Nachman
Novartis Oncology
Frances A. Shepherd, MD, FASCO
Stephen A. Sherwin, MD
Drs. Rachna and Puneet Shroff
Takeda Oncology

This list reflects commitments as of March 20, 2018.

This grant receives support that may result in a report to the CMS Open Payments website under the Physician Payments Sunshine Act. The supporting companies are required to report the amount of the grant, the names of physicians who are awarded this grant, and the names of their institutions. This information may appear on the Open Payments website. Find out more information about the Sunshine Act and CMS Open Payments program.